Diagnostic and therapeutic advances in growth hormone insensitivity

Endocrinol Metab Clin North Am. 2005 Sep;34(3):581-95, viii. doi: 10.1016/j.ecl.2005.04.009.

Abstract

Diagnostic and therapeutic advances in growth hormone insensitivity (GHI) have occurred principally in two areas: the molecular characterization of patients with GHI and treatment with recombinant human insulin like growth factor-I (IGF-I). This article discusses the current status of molecular diagnosis across the spectrum of the disorder. Treatment with recombinant human IGF-I in classical cases is summarized, and potential new targets for treatment are discussed together with the potential for therapy using the newly developed compound recombinant human IGF-I/IGF binding protein-3.

Publication types

  • Review

MeSH terms

  • Drug Therapy, Combination
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / therapeutic use
  • Insulin-Like Growth Factor I / therapeutic use
  • Laron Syndrome / diagnosis*
  • Laron Syndrome / drug therapy*
  • Laron Syndrome / etiology
  • Laron Syndrome / genetics
  • Mutation
  • Receptors, Somatotropin / chemistry
  • Receptors, Somatotropin / genetics
  • Receptors, Somatotropin / metabolism
  • Recombinant Proteins / therapeutic use

Substances

  • Insulin-Like Growth Factor Binding Protein 3
  • Receptors, Somatotropin
  • Recombinant Proteins
  • Insulin-Like Growth Factor I